Free Trial

Iovance Biotherapeutics (IOVA) Short Interest Ratio & Short Volume

Iovance Biotherapeutics logo
$2.15 -0.49 (-18.67%)
As of 09:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Iovance Biotherapeutics Short Interest Data

Iovance Biotherapeutics (IOVA) has a short interest of 98.63 million shares, representing 36.34% of the float (the number of shares available for trading by the public). This marks a 1.91% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 13.52 million shares to cover all short positions.

Current Short Interest
98,630,000 shares
Previous Short Interest
96,780,000 shares
Change Vs. Previous Month
+1.91%
Dollar Volume Sold Short
$191.34 million
Short Interest Ratio
5.7 Days to Cover
Last Record Date
July 15, 2025
Outstanding Shares
333,930,000 shares
Float Size
271,390,000 shares
Short Percent of Float
36.34%
Today's Trading Volume
2,388,855 shares
Average Trading Volume
13,519,325 shares
Today's Volume Vs. Average
18%
Short Selling Iovance Biotherapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Iovance Biotherapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

IOVA Short Interest Over Time

IOVA Days to Cover Over Time

IOVA Percentage of Float Shorted Over Time

Iovance Biotherapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202598,630,000 shares $191.34 million +1.9%36.3%5.7 $1.94
6/30/202596,780,000 shares $166.46 million +6.4%35.7%7.1 $1.72
6/15/202590,960,000 shares $203.75 million +5.3%33.5%6.9 $2.24
5/31/202586,360,000 shares $151.30 million +12.1%31.8%6.7 $1.75
5/15/202577,020,000 shares $135.56 million +3.3%28.4%5.8 $1.76
4/30/202574,570,000 shares $267.71 million +4.5%27.6%6.3 $3.59
4/15/202571,370,000 shares $230.53 million -5.1%26.9%7.4 $3.23
3/31/202575,190,000 shares $250.38 million +11.7%28.3%7.6 $3.33
3/15/202567,300,000 shares $241.61 million +12.9%25.3%7.2 $3.59
2/28/202559,590,000 shares $252.66 million -6.3%22.4%6.7 $4.24
2/15/202563,600,000 shares $354.25 million -0.5%25.7%8.6 $5.57
1/31/202563,910,000 shares $373.87 million +3.1%26.0%7.8 $5.85
1/15/202561,980,000 shares $366.30 million +1.1%25.1%8.1 $5.91
12/31/202461,310,000 shares $453.69 million +3.3%24.8%8.9 $7.40
12/15/202459,330,000 shares $464.55 million +4.2%24.0%9.6 $7.83
11/30/202456,920,000 shares $530.49 million +5.4%23.1%9.3 $9.32
11/15/202453,990,000 shares $441.64 million -9.6%21.9%8.6 $8.18
10/31/202459,730,000 shares $623.58 million -1.0%24.1%10.2 $10.44
10/15/202460,340,000 shares $578.66 million +0.7%24.4%10.1 $9.59
9/30/202459,950,000 shares $562.93 million -0.6%24.3%9.7 $9.39
9/15/202460,290,000 shares $623.40 million +4.5%24.4%8.9 $10.34
8/31/202457,690,000 shares $672.67 million -2.8%23.3%8 $11.66
8/15/202459,330,000 shares $633.05 million -3.3%24.5%8 $10.67
7/31/202461,320,000 shares $535.32 million +4.0%27.4%8.3 $8.73
7/15/202458,940,000 shares $511.60 million +4.5%26.4%9 $8.68
6/30/202456,420,000 shares $452.49 million +3.3%25.2%9 $8.02
6/15/202454,630,000 shares $445.78 million +9.4%24.4%9.3 $8.16
5/31/202449,960,000 shares $443.64 million -2.4%22.3%8.5 $8.88
5/15/202451,210,000 shares $546.92 million +2.3%22.9%7.8 $10.68
4/30/202450,060,000 shares $589.71 million +2.2%22.6%5.7 $11.78
4/15/202448,980,000 shares $582.37 million +5.6%22.2%5.5 $11.89
3/31/202446,380,000 shares $687.35 million -2.2%21.1%4.9 $14.82
3/15/202447,430,000 shares $659.75 million +1.5%21.6%4.6 $13.91
2/29/202446,710,000 shares $743.16 million +8.7%21.2%4.5 $15.91
2/15/202442,980,000 shares $424.21 million +2.4%20.1%4.4 $9.87
1/31/202441,970,000 shares $324.43 million -3.0%21.0%5.6 $7.73
1/15/202443,270,000 shares $389.86 million +18.8%21.7%5.7 $9.01
12/31/202336,410,000 shares $296.01 million +3.2%18.2%4.8 $8.13
12/15/202335,280,000 shares $274.48 million +2.0%17.7%5.1 $7.78
11/30/202334,590,000 shares $209.96 million -2.8%17.5%4.7 $6.07
Musk’s Project Colossus could mint millionaires (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.

All the details are waiting for you now — but you need to act before the September 1st funding windo
11/15/202335,590,000 shares $169.05 million -8.4%18.0%5.2 $4.75
10/31/202338,860,000 shares $148.45 million +0.3%19.4%6 $3.82
10/15/202338,740,000 shares $140.63 million +5.4%19.4%6.4 $3.63
9/30/202336,770,000 shares $167.30 million +20.5%18.4%6 $4.55
9/15/202330,510,000 shares $160.79 million +1.5%15.3%4.9 $5.27
8/31/202330,070,000 shares $181.62 million +9.2%14.7%6.2 $6.04
8/15/202327,530,000 shares $206.75 million -0.1%13.5%4.6 $7.51
7/31/202327,550,000 shares $200.01 million +6.1%13.6%4.6 $7.26
7/15/202325,960,000 shares $201.45 million -10.1%13.1%4.4 $7.76
6/30/202328,890,000 shares $203.39 million +12.8%14.6%5.1 $7.04
6/15/202325,620,000 shares $221.36 million +18.3%14.1%4.8 $8.64
5/31/202321,650,000 shares $189.22 million -7.4%11.9%4.4 $8.74
5/15/202323,380,000 shares $183.30 million No Change12.9%5.9 $7.84
10/31/202217,260,000 shares $161.21 million -5.0%12.2%8 $9.34
10/15/202218,170,000 shares $160.80 million -2.6%12.7%8.2 $8.85
9/30/202218,660,000 shares $178.76 million -4.5%13.0%8 $9.58
9/15/202219,540,000 shares $231.94 million -0.6%13.7%6.5 $11.87
8/31/202219,650,000 shares $210.65 million -5.4%13.7%5.6 $10.72
8/15/202220,760,000 shares $266.77 million +6.9%14.5%4.1 $12.85
7/31/202219,420,000 shares $226.24 million -2.6%14.0%3.8 $11.65
7/15/202219,940,000 shares $255.23 million -7.5%14.3%4.1 $12.80
6/30/202221,550,000 shares $237.91 million +30.1%15.5%4.4 $11.04
6/15/202216,560,000 shares $135.79 million -4.7%11.9%3.5 $8.20
5/31/202217,370,000 shares $117.25 million +1.0%12.5%4.6 $6.75
5/15/202217,200,000 shares $242.00 million +8.8%12.4%8.2 $14.07
4/30/202215,810,000 shares $239.52 million +3.7%11.4%7.7 $15.15
4/15/202215,250,000 shares $268.71 million +9.9%11.0%7.3 $17.62
3/31/202213,880,000 shares $231.10 million +1.5%N/A6.3 $16.65
3/15/202213,680,000 shares $171.14 million -0.3%9.9%6.7 $12.51
2/28/202213,720,000 shares $214.99 million +9.4%10.1%7 $15.67
2/15/202212,540,000 shares $223.96 million +11.6%9.2%6.3 $17.86
1/31/202211,240,000 shares $187.15 million -6.5%8.3%5.3 $16.65
1/15/202212,020,000 shares $186.19 million -3.6%N/A5.7 $15.49
12/31/202112,470,000 shares $238.05 million -6.9%9.1%6.7 $19.09
12/15/202113,390,000 shares $247.85 million -14.3%9.8%7.9 $18.51
11/30/202115,620,000 shares $292.41 million -1.1%11.5%9.5 $18.72
11/15/202115,800,000 shares $309.52 million +3.7%11.6%10.2 $19.59
10/29/202115,230,000 shares $370.24 million +0.3%11.1%11.2 $24.31
10/15/202115,190,000 shares $404.21 million +3.8%11.2%11.2 $26.61
9/30/202114,640,000 shares $361.02 million -5.5%10.8%10 $24.66
9/15/202115,490,000 shares $372.22 million -6.7%11.5%9.4 $24.03
8/31/202116,600,000 shares $399.56 million -2.0%12.3%9 $24.07
8/13/202116,940,000 shares $368.78 million -1.7%12.5%7.5 $21.77
7/30/202117,240,000 shares $383.93 million -3.5%12.7%4.8 $22.27
7/15/202117,860,000 shares $402.39 million +0.7%12.7%4.9 $22.53
6/30/202117,730,000 shares $461.33 million -14.4%12.6%4.8 $26.02
6/15/202120,720,000 shares $490.65 million -7.2%14.7%5.5 $23.68
5/28/202122,330,000 shares $414.67 million +11.0%15.9%6.1 $18.57
5/14/202120,120,000 shares $503.20 million +1.9%N/A5.8 $25.01
4/30/202119,750,000 shares $618.97 million -1.5%N/A9.7 $31.34
Musk’s Project Colossus could mint millionaires (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.

All the details are waiting for you now — but you need to act before the September 1st funding windo
4/15/202120,040,000 shares $601.00 million -6.0%N/A10.8 $29.99
3/31/202121,320,000 shares $631.92 million +43.3%N/A12 $29.64
3/15/202114,880,000 shares $516.19 million +6.4%N/A10.1 $34.69
2/26/202113,980,000 shares $510.41 million +9.4%N/A10 $36.51
2/12/202112,780,000 shares $610.25 million -9.0%N/A10.3 $47.75
1/29/202114,050,000 shares $613.28 million -8.4%N/A11.7 $43.65
1/15/202115,340,000 shares $798.14 million -1.2%N/A12.8 $52.03
12/31/202015,530,000 shares $757.24 million -5.4%N/A12 $48.76
12/15/202016,410,000 shares $824.77 million -2.2%N/A10.9 $50.26
11/30/202016,780,000 shares $660.80 million +1.3%N/A12.1 $39.38
11/15/202016,570,000 shares $625.02 million -0.1%N/A11.7 $37.72
10/30/202016,590,000 shares $595.25 million +9.4%N/A11.9 $35.88
10/15/202015,160,000 shares $524.54 million +17.3%N/A10.9 $34.60
9/30/202012,920,000 shares $425.33 million -7.0%N/A10.2 $32.92
9/15/202013,890,000 shares $496.15 million -4.6%N/A10.4 $35.72
8/31/202014,560,000 shares $485.28 million +1.0%N/A10 $33.33
8/14/202014,410,000 shares $400.45 million +3.2%N/A8 $27.79

IOVA Short Interest - Frequently Asked Questions

What is Iovance Biotherapeutics' current short interest?

Short interest is the volume of Iovance Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 98,630,000 shares of IOVA short. 36.34% of Iovance Biotherapeutics' shares are currently sold short. Learn More on Iovance Biotherapeutics' current short interest.

What is a good short interest ratio for Iovance Biotherapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IOVA shares currently have a short interest ratio of 6.0. Learn More on Iovance Biotherapeutics's short interest ratio.

Which institutional investors are shorting Iovance Biotherapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Iovance Biotherapeutics: Simplex Trading LLC, Jane Street Group LLC, Caption Management LLC, Walleye Trading LLC, Walleye Capital LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Iovance Biotherapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 36.34% of Iovance Biotherapeutics' floating shares are currently sold short.

Is Iovance Biotherapeutics' short interest increasing or decreasing?

Iovance Biotherapeutics saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 98,630,000 shares, an increase of 1.9% from the previous total of 96,780,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Iovance Biotherapeutics' float size?

Iovance Biotherapeutics currently has issued a total of 333,930,000 shares. Some of Iovance Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Iovance Biotherapeutics currently has a public float of 271,390,000 shares.

How does Iovance Biotherapeutics' short interest compare to its competitors?

36.34% of Iovance Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Iovance Biotherapeutics: SpringWorks Therapeutics (9.19%), Scholar Rock Holding Corporation (14.92%), MoonLake Immunotherapeutics (11.98%), Protagonist Therapeutics, Inc. (9.97%), Apellis Pharmaceuticals, Inc. (13.06%), HUTCHMED (China) Limited Sponsored ADR (0.20%), Kymera Therapeutics, Inc. (11.62%), Immunovant, Inc. (29.97%), Ultragenyx Pharmaceutical Inc. (9.31%), Alvotech (1.55%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks.

What does it mean to sell short Iovance Biotherapeutics stock?

Short selling IOVA is an investing strategy that aims to generate trading profit from Iovance Biotherapeutics as its price is falling. IOVA shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Iovance Biotherapeutics?

A short squeeze for Iovance Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IOVA, which in turn drives the price of the stock up even further.

How often is Iovance Biotherapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IOVA, twice per month. The most recent reporting period available is July, 15 2025.




This page (NASDAQ:IOVA) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners